Adrian T Billeter1, Beatrice Reiners1, Svenja E Seide2, Pascal Probst1,3, Eva Kalkum3, Christian Rupp4, Beat P Müller-Stich1. 1. Department of General, Visceral and Transplant Surgery, University of Heidelberg, Heidelberg, Germany. 2. Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany. 3. The Study Center of the German Surgical Society (SDGC), Heidelberg, Germany. 4. Department of Gastroenterology and Hepatology, University of Heidelberg, Heidelberg, Germany.
Abstract
Background: Non-alcoholic steatohepatitis (NASH) comprises a major healthcare problem affecting up to 30% of patients with obesity and the associated risk for cardiovascular and liver-related mortality. Several new drugs for NASH-treatment are currently investigated. No study thus far directly compared surgical and non-surgical therapies for NASH. This network meta-analysis compares for the first time the effectiveness of different therapies for NASH using a novel statistical approach. Methods: The study was conducted according to the PRISMA guidelines for network meta-analysis. PubMed, CENTRAL and Web of Science were searched without restriction of time or language using a validated search strategy. Studies investigating therapies for NASH in adults with liver biopsies at baseline and after at least 12 months were selected. Patients with liver cirrhosis were excluded. Risk of bias was assessed with ROB-2 and ROBINS-I-tools. A novel method for population-adjusted indirect comparison to include and compare single-arm trials was applied. Main outcomes were NASH-resolution and improvement of fibrosis. Results: Out of 7,913 studies, twelve randomized non-surgical studies and twelve non-randomized surgical trials were included. NASH-resolution after non-surgical intervention was 29% [95% confidence interval (CI): 23-40%] and 79% (95% CI: 72-88%) after surgery. The network meta-analysis showed that surgery had a higher chance of NASH-resolution than medication [odds ratio (OR) =2.68; 95% CI: 1.44-4.97] while drug treatment was superior to placebo (OR =2.24; 95% CI: 1.55-3.24). Surgery (OR =2.18; 95% CI: 1.34-3.56) and medication (OR =1.79; 95% CI: 1.39-2.31) were equally effective to treat fibrosis compared to placebo without difference between them. The results did not change when only new drugs specifically developed for the treatment of NASH were included. Conclusions: Metabolic surgery has a higher effectiveness for NASH-therapy than medical therapy while both were equally effective regarding improvement of fibrosis. Trials directly comparing surgery with medication must be urgently conducted. Patients with NASH should be informed about surgical treatment options. 2022 Hepatobiliary Surgery and Nutrition. All rights reserved.
Background: Non-alcoholic steatohepatitis (NASH) comprises a major healthcare problem affecting up to 30% of patients with obesity and the associated risk for cardiovascular and liver-related mortality. Several new drugs for NASH-treatment are currently investigated. No study thus far directly compared surgical and non-surgical therapies for NASH. This network meta-analysis compares for the first time the effectiveness of different therapies for NASH using a novel statistical approach. Methods: The study was conducted according to the PRISMA guidelines for network meta-analysis. PubMed, CENTRAL and Web of Science were searched without restriction of time or language using a validated search strategy. Studies investigating therapies for NASH in adults with liver biopsies at baseline and after at least 12 months were selected. Patients with liver cirrhosis were excluded. Risk of bias was assessed with ROB-2 and ROBINS-I-tools. A novel method for population-adjusted indirect comparison to include and compare single-arm trials was applied. Main outcomes were NASH-resolution and improvement of fibrosis. Results: Out of 7,913 studies, twelve randomized non-surgical studies and twelve non-randomized surgical trials were included. NASH-resolution after non-surgical intervention was 29% [95% confidence interval (CI): 23-40%] and 79% (95% CI: 72-88%) after surgery. The network meta-analysis showed that surgery had a higher chance of NASH-resolution than medication [odds ratio (OR) =2.68; 95% CI: 1.44-4.97] while drug treatment was superior to placebo (OR =2.24; 95% CI: 1.55-3.24). Surgery (OR =2.18; 95% CI: 1.34-3.56) and medication (OR =1.79; 95% CI: 1.39-2.31) were equally effective to treat fibrosis compared to placebo without difference between them. The results did not change when only new drugs specifically developed for the treatment of NASH were included. Conclusions: Metabolic surgery has a higher effectiveness for NASH-therapy than medical therapy while both were equally effective regarding improvement of fibrosis. Trials directly comparing surgery with medication must be urgently conducted. Patients with NASH should be informed about surgical treatment options. 2022 Hepatobiliary Surgery and Nutrition. All rights reserved.
Authors: A T Billeter; K M Scheurlen; P Probst; S Eichel; F Nickel; S Kopf; L Fischer; M K Diener; P P Nawroth; B P Müller-Stich Journal: Br J Surg Date: 2018-02 Impact factor: 6.939
Authors: Daniel Gero; Dimitri A Raptis; Wouter Vleeschouwers; Sophie L van Veldhuisen; Andres San Martin; Yao Xiao; Manoela Galvao; Marcoandrea Giorgi; Marine Benois; Felipe Espinoza; Marianne Hollyman; Aaron Lloyd; Hanna Hosa; Henner Schmidt; José Luis Garcia-Galocha; Simon van de Vrande; Sonja Chiappetta; Emanuele Lo Menzo; Cristina Mamédio Aboud; Sandra Gagliardo Lüthy; Philippa Orchard; Steffi Rothe; Gerhard Prager; Dimitri J Pournaras; Ricardo Cohen; Raul Rosenthal; Rudolf Weiner; Jacques Himpens; Antonio Torres; Kelvin Higa; Richard Welbourn; Marcos Berry; Camilo Boza; Antonio Iannelli; Sivamainthan Vithiananthan; Almino Ramos; Torsten Olbers; Matias Sepúlveda; Eric J Hazebroek; Bruno Dillemans; Roxane D Staiger; Milo A Puhan; Ralph Peterli; Marco Bueter Journal: Ann Surg Date: 2019-11 Impact factor: 12.969
Authors: Soraya Rodrigues de Almeida; Paulo Roberto Savassi Rocha; Marcelo Dias Sanches; Virgínia Hora Rios Leite; Rogério Augusto Pinto da Silva; Marco Túlio Costa Diniz; Maria de Fátima Haueisen Sander Diniz; Alexandre Lages Savassi Rocha Journal: Obes Surg Date: 2006-03 Impact factor: 4.129
Authors: Erland Erdmann; Bernard Charbonnel; Robert G Wilcox; Allan M Skene; Massimo Massi-Benedetti; John Yates; Meng Tan; Robert Spanheimer; Eberhard Standl; John A Dormandy Journal: Diabetes Care Date: 2007-07-31 Impact factor: 19.112
Authors: Myriam Alexander; A Katrina Loomis; Johan van der Lei; Talita Duarte-Salles; Daniel Prieto-Alhambra; David Ansell; Alessandro Pasqua; Francesco Lapi; Peter Rijnbeek; Mees Mosseveld; Dawn M Waterworth; Stuart Kendrick; Naveed Sattar; William Alazawi Journal: BMC Med Date: 2019-05-20 Impact factor: 8.775
Authors: Raj Vuppalanchi; Marshall E McCabe; Sweta R Tandra; Siva P Parcha; Adil Ghafoor; Leslie Schuh; Margaret M Inman; Don J Selzer; Dimitrios Stefanidis; Naga Chalasani Journal: Ann Surg Date: 2022-01-01 Impact factor: 12.969